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Breast cancer is a highly heterogeneous neoplasm with different response to chemotherapy. In this study, we 
investigated if homologous recombination repair (HRR), one of the important pathways of DNA damage repair, 
could serve as biomarkers for breast cancer. Breast cancer patients were selected from the Cancer Genome Atlas 
(TCGA) database.  Data of RNA-seq or mutation alteration of HRR pathway-related genes were extracted and 
analyzed. Correlations between HRR pathway mutation and clinicopathological features of breast cancer were 
analyzed using chi-square test. Based on the Kaplan-Meier method and log-rank test, survival analysis was done 
to identify the correlation between each HRR gene and survival rates. Using data retrieved from TCGA database, 
1108 cases were identified of breast cancer with full data on RNA-seq and 986 cases with full data on mutation. 
We demonstrated that high expression of HRR gene RAD50, RAD51, RAD51C, RAD54L and XRCC2 were 
associated with favorable prognosis (Log-rank P=0.02686, 0.03734, 0.00664, 0.01147 and 0.01818, respectively). 
Moreover, mutation in the HRR pathway was present in 15.0% of cases. RIM1, PPP4R2, PPP4R4, RAD50 and 
RAD51D gene mutation were associated with unfavorable outcome (Log-rank P=0.0346, 0.0051, 0.0326, 0.0213 
and 0.0007, respectively). The N stage and estrogen receptor (ER) status were significantly related to HRR 
pathway mutation (all factors P<0.05). Additionally, basal-like breast cancer subtype took up more percentage 
in HRR pathway mutation patients. Low expression or mutation in HRR pathway were associated with 
unfavorable prognosis in breast cancer. HRR pathway could serve as potential predictor, emphasizing the 
significance of more research on HRR pathway genes to facilitate more profound clinical implications in breast 
cancer molecular treatment. 
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Breast cancer is an important public health threat to women 
worldwide and is the second leading cause of cancer-related 
morality, accounting for an estimated 268,600 new cases and 
41,760 deaths in 2019 [1]. Multiple studies have confirmed 
that breast cancer is a highly heterogeneous malignant tumor 
which is constitutive of different subtypes according to 
estrogen receptor (ER) status, progesterone receptor (PR) 
status and HER2 status, with diverse clinical performance, 
biological characteristics and prognosis [2]. Despite great 
improvement have been achieved in breast cancer treatment, 
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which includes chemotherapy, radiation therapy, endocrine 
therapy, molecular targeted therapy and the emerging 
immunotherapies, response to therapies varied widely [3]. 
Therefore, identification of novel biomarkers for therapeutic 
targets and efficacy prediction of breast cancer is urgently 
required.  
Alterations in DNA damage response, especially in 
homologous recombination repair (HRR), are discovered in 
various cancers and have been targeted effectively. For 
example, the poly(ADP-ribose) polymerase (PARP) inhibitor 
has exhibited remarkable benefit in BRCA1/2 mutated ovarian 
and breast cancer [4-6]. The intrinsic mechanism underlying 
this novel molecular inhibitor could be the effect of synthetic 
lethality. In normal cells, DNA damage breaks (DSBs) are 
immediately repaired with a proficient HRR mechanism. 
However, in tumors lacking HRR, the left un-repaired DNA 
damage could not be effectively restored, which ultimately 
accumulates and lead to cell death [7]. Moreover, Guo et al 
indicated that certain biomarkers in HRR could predict 
response to chemotherapy and select potential patients in 
early-phase treatment [8]. However, as far as we known, most 
of HRR genes, except BRCA1/2 [9], have not yet been fully 
understand to date.  
On the other hand, the mainstream studies of BRCA1/2 
mainly focused on triple-negative breast cancer, which was 
characterized with ER negative, PR negative and HER2 
negative and associated with elevated gene mutation [10, 11]. 
Nevertheless, Timms et al established that HRR showed close 
association with BRCA1/2 mutation regardless of breast 
cancer subtype [12]. Hence, more expanded studies are needed 
to facilitate the precise clinical applications of HRR in all 
breast cancer subtypes. 
In this study, The Cancer Genome Atlas (TCGA) was 
investigated to examine the prevalence and the clinical 
significance of HRR pathway alteration in breast cancer cases. 
HRR pathway alterations were elaborated from two aspects of 
mRNA expression and mutation respectively. We 
demonstrated that low expression or mutation in HRR 
pathway were associated with unfavorable prognosis in breast 
cancer, indicating the importance of more research on HRR 
pathway in breast cancer molecular treatment.  
Materials and Methods 
Patients and Samples 
Breast cancer tissue samples with RNA‑seq data, mutation 
data and clinicopathological information were downloaded 
from the cancer genome atlas (TCGA) database released on 
October 31, 2019. The HRR-related genes included in the 
study were BLM, BRCA1, BRCA2, DMC1, EME1, EME2, 
GEN1, HFM1, MRE11, MUS81, NBN, PPP4C, PPP4R1, 
PPP4R2, PPP4R4, RAD50, RAD51, RAD51B, RAD51C, 
RAD51D, RAD52, RAD54B, RAD54L, RAD54L2, RDM1, 
RECQL, RECQL4, RECQL5, RMI1, RMI2, RPA1, RPA2, 
RPA3, SEM1, SLX1A, SLX4, PPP4R3A, PPP4R3B, SPO11, 
TOP3A, TOP3B, WRN, XRCC2 and XRCC3. All patients’ 
clinicopathological information including age, menopause 
status, T stage, N stage, M stage, tumor-node-metastasis 
(TNM) stage, ER status, PR status, HER2 status and OS data 
were comprised. OS was measured from the date of diagnosis 
to the date of death due to all causes or the last follow-up. 
Statistical analysis 
The gene expression data were expressed as mean standard 
variation. Samples with full data on mutation alteration of 
HRR pathway were included in the study and were categorized 
into two groups, the first being wild (no alteration) and the 
second being mutation (any gene mutation in the HRR 
pathway). Correlations between HRR gene mutation status 
and clinicopathological features of breast cancer were 
analyzed through using chi-square test. For survival analysis 
based on expression of a single gene, patients were 
dichotomized as having low or high expression using a gene-
specific cut-off value which was generated from the lowest 
log-rank P value of a series of 10 cut-offs spaced evenly 
between the maximum and minimum expression value. 
Survival analysis was performed using the Kaplan-Meier 
method and the log-rank test. All P values were two sided, and 
P<0.05 was considered statistically significant. All the 
statistical analysis was performed using SPSS version 22.0 
software (IBM Corp.) and R 3.4.2. 
Results 
Homologous recombination repair pathway gene expression 
level in breast cancer patients 
Analysis of gene mRNA expression and overall survival 
was conducted in 1108 tumor samples with complete RNA-
seq data retrieved from TCGA. The HRR pathway gene list 
was mainly based on a published article that summarized the 
genes related to homologous recombination repair, which 
including 44 genes (Figure 1A). Most of the HRR genes has 
not been fully studied to date. Therefore, the association of 
each HRR gene and OS was analyzed. We reported that that 
high expression of five HRR gene RAD50, RAD51, RAD51C, 
RAD54L and XRCC2 were significantly associated with 
favorable prognosis (Log-rank P=0.02686, 0.03734, 0.00664, 
0.01147 and 0.01818, respectively, Figure2A-E) in breast 
cancer samples. 
Homologous recombination repair pathway gene mutation in 
breast cancer patients 
Analysis of HRR gene mutation and OS was conducted in  
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Figure 1. A: Gene list of HRR pathway. B: TOP 10 mutated genes in HRR pathway. 
 
 
Figure 2. Analysis of homologous recombination repair pathway gene expression and Kaplan-Meier estimates of overall survival in breast 
cancer patients. A: RAD50. B: RAD51. C: RAD51C. D: RAD54L. E: XRCC2. 
 
968 tumor samples. The overall incidence of HRR pathway 
mutation of breast cancer in the TCGA database was 15.0%. 
Among all the altered genes, the most frequently involved 
genes were BRCA1, followed by BRCA2, BLM1, RAD50 
and RAD54B (15.5%, 14.9%, 8.8%, and 8.1%, respectively, 
Figure1B). We analyzed each gene mutation and its relation 
with overall survival. RIM1, PPP4R2, PPP4R4, RAD50 and 
RAD51D gene mutation were significantly associated with 
unfavorable outcome in breast cancer patients (Log-rank 
P=0.0346, 0.0051, 0.0326, 0.0213 and 0.0007, respectively,  
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Figure 3. Analysis of homologous recombination repair pathway gene mutation status and survival in breast cancer patients. A: RIM1. B: 
PPP4R2. C: PPP4R4. D: RAD50. E: RAD51D.  
 
Figure3A-E). Furthermore, we merged each HRR gene 
mutation to define the HRR pathway mutation and 
demonstrated that the mutation of HRR pathway was not 
significantly associated with overall survival in breast cancer 
(P=0.3029, Figure3F).  
Relationship between homologous recombination repair 
pathway gene mutation status and clinicopathological 
features 
We further evaluated whether HRR pathway gene mutation 
was associated with the clinical development and progression 
of breast cancer. The clinicopathological features of HRR 
pathway mutation or wild patients were summarized in table1. 
The N stage (c2=6.677, P=0.010) and estrogen receptor (ER) 
status (c2=4.280, P=0.039) were significantly related to HRR 
pathway mutation status (Table 1). However, the age, 
menopause status, T stage, M stage, PR status and HER2 
status had no significant correlation with HRR pathway 
mutation (Table 1). Furthermore, we evaluated if the 
pathological types of breast cancer were related to HRR 
mutation status. In HRR pathway mutation samples, basal-like 
type breast cancer ranked 3rd and accounted for 23.58% of all 
breast cancer types, compared with 4th and 13.59% in HRR 
pathway wild breast cancer patients (Figure4A-B). 
Discussion 
The hereditary breast cancer is associated with the presence 
of germline mutations in BRCA1 or BRCA2 genes, which 
both taking part in the HRR pathway to repair DNA damage 
and maintaining genomic stability. Biomarkers of HRR have 
been investigated in breast cancer to determine if they might 
be able to select patients for therapies targeting tumors with 
defective DNA repair, including platinum and PARP 
inhibitors [13].  
In the present study, we investigated the clinical 
implications of the alteration of HRR pathway in breast cancer 
using the TCGA database. We illustrated that alterations of 
HRR gene RAD50 and RAD51 were significantly associated 
with prognosis in breast cancer. As one of the important com-  
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No. % No. % 
Age     1.273 0.259 
≤59 years 74 50.0 461 55.0   
>59 years 74 50.0 377 45.0   
Menopause status     1.497 0.473 
pre 29 19.6 184 22.0   
post 96 64.9 520 62.1   
peri 3 2.0 31 3.7   
Missing 20  103    
T stage     0.040 0.842 
T1-T2 124 83.8 705 84.1   
T3-T4 24 16.2 130 15.5   
Missing -  3    
N stage     6.677 0.010 
N0 83 56.1 375 44.7   
N1-3 62 41.9 447 53.3   
Missing 3  16    
M stage     0.421 0.516 
M0 122 82.4 704 84.0   
M1 4 2.7 16 1.9   
Missing 22  118    
TNM stage b     2.617 0.106 
I-II 118 79.7 613 73.2   
III-IV 28 18.9 209 25.0   
Missing 2  16    
ER status c     4.280 0.039 
negative 36 24.3 111 13.2   
positive 80 54.1 394 47.0   
Missing 32  333    
PR status d     2.641 0.104 
negative 46 31.1 158 18.9   
positive 71 48.0 344 41.1   
Missing 31  336    
HER-2 status e     1.666 0.197 
negative 90 60.8 427 51.0   
positive 21 14.2 70 8.4   
Missing 37  341    
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Figure 4. Percentages of different subtypes of breast cancer in HRR mutation (A) and wild patients (B). 
 
ponents of multi-protein complex MRE11-RAD50-NBS1 
(MRN), Rad50 is a DNA damage repair protein, acting as the 
main sensor of DSB. MRN involved in two major pathways 
after DNA damage repair (NHEJ, non-homologous 
recombination repair and HRR, homologous recombination 
repair), and plays an important role in telomerase maintenance, 
normal mitosis and cell cycle regulation [14]. In addition, 
Rad51, which has many homologs of XRCC2, XRCC3, 
Rad51B, Rad51C, Rad51D, Rad52 and Rad54, contributed to 
the HRR process. Previous studies have shown that Rad51 
protein and its homologs played an important role in 
catalyzing homologous pairing in vivo. The formation of 
Rad51 nuclear foci after DNA damage was particularly 
necessary for homologous recombination repair [15]. 
Therefore, taken together, our results implicated that RAD50 
and RAD51 showed promising potential to serve as clinical 
predictors in breast cancer treatment of DNA damage agents, 
which warrants future prospective investigation. 
Interestingly, low expression and mutation of HRR genes 
was associated unfavorable outcome in breast cancer. 
However, some studies shown that Rad51 gene mutation play 
a weak role in the evolution of tumors, so the potential 
relationship between them is probably resulting from 
transcription and protein level. The specific mechanism of 
them still remained controversial [16]. It might be speculated 
that multiple signaling pathways and physiological processes 
of cells will be activated due to DNA damage caused by 
various carcinogenic factors. Tumors occur because the DNA 
repair system cannot maintain a relatively balanced state with 
the physiological processes of the cell for a long time. 
Moreover, clinicopathological analysis identified that N 
stage and ER status were significantly related to HRR pathway 
mutation status, with basal-like type breast cancer taking up 
more percentage in HRR pathway mutation patients. Basal-
like breast cancer was particularly aggressive in biological 
characteristics. Chandler et al reported that basal-like breast 
cancer could impair HRR and repair efficiency through a small 
molecular inhibitor, and decreased the formation of Rad51 
foci [17]. Therefore, this type of breast cancer might benefit 
more from HRR pathway.  
Additionally, our study had some deficiencies in some 
aspects. On one hand, samples of HRR mutations are not large 
enough, which would lead to study bias. On the other hand, 
homologous recombination deficiency has some standard 
measurement, which consists of HRD-loss of heterozygosity 
score (LOH), HRD-telomeric allelic imbalance score (TAI), 
and HRD-large-scale state transition score (LST) [18]. 
Therefore, our statistical analysis has many limitations, which 
required more experimental and clinical researches in the 
future.  
As HRR might be the ideal candidate to select patients who 
may benefit from treatment of PARP inhibitors and other 
DNA damage molecular therapies, Some studies indicated that 
tumors harboring HRR are supposed to have a higher number 
of mutations, hence a higher tumor mutational burden, which 
could potentially make them more sensitive to immunotherapy 
[19]. Therefore, further studies are needed to validate novel 
functional biomarkers in the clinic. Our data suggest that these 
biomarkers should potentially be considered independently in 
future clinical trials.  
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